{
    "nctId": "NCT04588298",
    "briefTitle": "A Study to Investigate the Biological Effects of AZD9833 in Women With ER-positive, HER2 Negative Primary Breast Cancer",
    "officialTitle": "A Randomised, Open-Label, Parallel-Group, Pre-surgical Study to Investigate the Biological Effects of AZD9833 in Women With ER-positive, HER2-negative Primary Breast Cancer (SERENA-3)",
    "overallStatus": "COMPLETED",
    "conditions": "HER2-negative Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 135,
    "primaryOutcomeMeasure": "Change from baseline in estrogen receptor (ER) expression between pre- and on-treatment tumour samples measured by immunohistochemistry (IHC)",
    "eligibilityCriteria": "Inclusion criteria:\n\n* Provision of written informed consent prior to study entry\n* Female participants aged at least 18 years\n* Post-menopausal status defined as meeting at least one of the following criteria:\n\n  1. Have undergone a bilateral oophorectomy\n  2. Age \u2265 60 years\n  3. Age \u2265 50 and \\< 60 years and with cessation of menses \u2265 12 months and follicle-stimulating hormone and oestradiol levels in the post-menopausal range and with an intact uterus in the absence of oral contraception or hormone replacement therapy prior to the diagnosis of breast cancer\n* Female participants with newly diagnosed primary breast cancer scheduled to undergo treatment with curative intent by surgery and irrespective of clinical node status\n* Histologically confirmed invasive breast cancer involving a palpable tumour of any size, or a tumour with an ultrasound assessed diameter of \u2265 1.0 cm\n* Participants with adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours curatively treated with no evidence of disease for \u2265 3 months can be considered for the study\n* According to the local laboratory participants must have:\n\n  1. ER positive breast cancer\n  2. HER2-negative breast cancer\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1\n\nExclusion Criteria:\n\n* Previous systemic or local treatment for the new primary breast cancer currently under investigation (including surgery, radiotherapy, cytotoxic and endocrine treatments)\n* Intervention with any of the following:\n\n  1. Use of sex-hormone-containing drugs within 6 months prior to the first dose of study treatment\n  2. Medications or herbal supplements known to be strong inhibitors/inducers of CYP3A4/5, sensitive CYP2B6 substrates and drugs which are substrates of CYP2C9 and/or CYP2C19 which have a narrow therapeutic index\n  3. Drugs that are known to prolong QT and have a known risk of torsades de pointes\n* Inflammatory breast cancer\n* Any evidence of severe or uncontrolled systemic diseases which in the investigator's opinion makes it undesirable for the participant to participate in the study\n* Any of the following cardiovascular criteria: Mean resting QTcF \\> 470 msec; resting heart rate of \\< 50 bpm for stages 1 and 2 at screening;resting heart rate \\<60 bpm at screening for Stage 3; any clinically important abnormalities in rhythm, conduction, or morphology of resting ECG; any factors that increase the risk of QTc prolongation or risk of arrhythmic events; known left ventricular ejection fraction \\< 50%; significant cardiovascular procedure or event within the last 6 months; uncontrolled hypertension or symptomatic hypotension\n* Inadequate bone marrow reserve or organ function\n* Refractory nausea and vomiting, uncontrolled chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of AZD9833\n* History of hypersensitivity to active or inactive excipients of AZD9833\n* Previous randomisation in the present study\n* Judgement by the Investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions and requirements",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}